Loading market data...
Saturday, August 29, 2026
Back to HomeStock AnalysisPremiumAll Thermo Fisher Scientific coverage

Thermo Fisher (TMO) Q2 2026: Organic Growth 5%, Cash Falls 59%

Share
Thermo Fisher (TMO) Q2 2026: Organic Growth 5%, Cash Falls 59%

Thermo Fisher (TMO) Q2 2026: Organic Growth 5%, Cash Falls 59%

Thermo Fisher grew revenue 10% in the second quarter, but only half of that was earned rather than bought. The company's own reconciliation splits the gain into 5 points organic, 4 points acquisitions and 1 point currency. The organic number is the one that matters, and it marks a genuine turn. The company discloses 5% organic growth for the quarter and 3% for the six months; backing out the first quarter implies organic growth there of roughly 1%, though both inputs are rounded to whole points so the derived figure carries a wide band. Directionally, the second quarter marks a clear acceleration in the underlying business. The bill arrived on the balance sheet, where cash fell from $9,852 million to $4,064 million and net debt rose 31% in six months to fund the $9,098 million Clario acquisition.

A timing note governs every comparison below. Clario closed March 24, 2026, four days before the first quarter ended. Its cash outflow and goodwill were booked in Q1; Q2 is the first full quarter carrying both its revenue and its amortization. Income statement comparisons are three-month unless stated. Balance sheet and cash flow movements are six-month changes from December 31, 2025.


1. Balance Sheet

1-1. Asset composition

ItemDec 31, 2025 ($M)Jun 27, 2026 ($M)Change %
Cash and cash equivalents9,8524,064-58.8%
Short-term investments253-100.0%
Accounts receivable, net8,9009,451+6.2%
Inventories5,4255,627+3.7%
Property, plant and equipment, net10,56510,755+1.8%
Acquisition-related intangible assets, net15,83818,606+17.5%
Goodwill49,36254,832+11.1%
Total assets110,343113,174+2.6%

The $5,788 million cash drawdown has two causes. Acquisitions took $8,872 million net of cash acquired, and share repurchases took $4,000 million. Clario's $9,098 million price consisted of $5,806 million cash, $3,180 million of target debt settled at closing, a $121 million payable and $108 million of contingent consideration, less $117 million of cash acquired.

Unlimited U.S.-market analysis, $9.99/month

Thermo Fisher (TMO) Q2 2026: Organic Growth 5%, Cash Falls 59%

This article became available on August 29, 2026. Subscribe to read in full, or wait until November 27, 2026 when it becomes free.

Cancel anytime. Full refund within 7 days.

Access is tied to your account. Subscribe with the same email you sign up with — if you already paid, sign up with that email and it unlocks automatically.

NewsFinanceMarkets

Go deeper than the headline

You just read what happened. Here's how to read what it means.

Free daily briefing

The U.S. market, every morning — free

LineVest Daily lands in your inbox before every opening bell: the key U.S. markets stories, earnings, disclosures and foreign flows — in plain English. Free, no card required.

Get LineVest Daily — free →
This company

Full report on Thermo Fisher Scientific

We read Thermo Fisher Scientific's latest SEC filing in full — financials under US GAAP, governance, and what it means for the stock. PDF in your inbox within 3 hours.

$12 · one-time

Get the Thermo Fisher Scientific report
Every name you watch

Follow the whole market

Reading several U.S. stocks a week? Read every analysis article the moment it publishes — full daily U.S. market coverage plus the 90-day archive.

$9.99 · monthly

Subscribe

Independent journalism based on primary SEC filings — not investment advice. No brokerage affiliation.